WO2000072799A3 - Method and compositions for treating the inflammatory response - Google Patents

Method and compositions for treating the inflammatory response Download PDF

Info

Publication number
WO2000072799A3
WO2000072799A3 PCT/US2000/014548 US0014548W WO0072799A3 WO 2000072799 A3 WO2000072799 A3 WO 2000072799A3 US 0014548 W US0014548 W US 0014548W WO 0072799 A3 WO0072799 A3 WO 0072799A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory response
compositions
treating
pde
phosphodiesterase
Prior art date
Application number
PCT/US2000/014548
Other languages
French (fr)
Other versions
WO2000072799A2 (en
Inventor
Joel M Linden
Gail W Sullivan
Ian J Sarembock
W Michael Scheld
Original Assignee
Univ Virginia
Joel M Linden
Gail W Sullivan
Ian J Sarembock
W Michael Scheld
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia, Joel M Linden, Gail W Sullivan, Ian J Sarembock, W Michael Scheld filed Critical Univ Virginia
Priority to AU52941/00A priority Critical patent/AU5294100A/en
Publication of WO2000072799A2 publication Critical patent/WO2000072799A2/en
Publication of WO2000072799A3 publication Critical patent/WO2000072799A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Agonists of A2A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the treatment of the inflammatory response of mammalian tissue.
PCT/US2000/014548 1999-05-27 2000-05-26 Method and compositions for treating the inflammatory response WO2000072799A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52941/00A AU5294100A (en) 1999-05-27 2000-05-26 Method and compositions for treating the inflammatory response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32076999A 1999-05-27 1999-05-27
US09/320,769 1999-05-27

Publications (2)

Publication Number Publication Date
WO2000072799A2 WO2000072799A2 (en) 2000-12-07
WO2000072799A3 true WO2000072799A3 (en) 2001-07-12

Family

ID=23247801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014548 WO2000072799A2 (en) 1999-05-27 2000-05-26 Method and compositions for treating the inflammatory response

Country Status (2)

Country Link
AU (1) AU5294100A (en)
WO (1) WO2000072799A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
ATE381336T1 (en) * 2002-04-10 2008-01-15 Univ Virginia USE OF A2A ADENOSINE RECEPTOR AGONIST AND ANTIPATHOGENE CONTAINING COMBINATIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
CA2576826C (en) 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
KR20070085839A (en) * 2004-11-08 2007-08-27 캔-파이트 바이오파마 리미티드 Therapeutic treatment of accelerated bone resorption
EP2021350B1 (en) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
NZ600394A (en) 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP2011513493A (en) * 2008-03-10 2011-04-28 コーネル ユニバーシティー How to regulate blood-brain barrier permeability
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20230021159A (en) 2009-11-27 2023-02-13 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CN102946875A (en) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 Combination therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (en) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Medical use of DPP-4 inhibitors
JP2019517542A (en) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of linagliptin and metformin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057651A1 (en) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
WO1999034804A1 (en) * 1998-01-08 1999-07-15 The University Of Virginia Patent Foundation A2a adenosine receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
WO1998057651A1 (en) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
WO1999034804A1 (en) * 1998-01-08 1999-07-15 The University Of Virginia Patent Foundation A2a adenosine receptor agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUSTER B(A) ET AL: "The effect of adenosine receptor agonists on neutrophil pleocytosis and blood-brain barrier pathophysiology in experimental bacterial meningitis", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,XX,XX, vol. 37, 1997, pages 39, XP002104913 *
SULLIVAN ET AL.: "Neutrophil A2a adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with type IV phosphodiesterase inhibitor , Rolipram", JOURNAL OF INFECTIOUS DISEASES, vol. 180, no. 5, November 1999 (1999-11-01), pages 1550 - 1560, XP000978330 *
SULLIVAN ET AL.: "Role of A2a adenosine receptors in inflammation", DRUG DEVELOPMENT RESEARCH, vol. 45, no. 3-4, 1998, pages 103 - 112, XP000978332 *
SULLIVAN GW ET AL: "The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY,US,ELMSFORD,NY, vol. 17, no. 10, 1995, pages 793 - 803, XP002104914, ISSN: 0192-0561 *

Also Published As

Publication number Publication date
WO2000072799A2 (en) 2000-12-07
AU5294100A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
WO2000072799A3 (en) Method and compositions for treating the inflammatory response
AU6230098A (en) Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
WO2002102314A3 (en) Purine inhibitors of phosphodiesterase (pde) 7
CA2400554A1 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
GB9823873D0 (en) 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EE200200192A (en) 5- (2-Substituted-5-heterocyclylsulfonylpyrid-3-yl) dihydropyrazolo [4,3-d] pyrimidin-7-ones as phosphodiesterase inhibitors
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
AP2000001753A0 (en) 2,3-Diaryl-pyrazolo (1,5-b) pyridazines derivatives their preparation and their use as cycooxygenase 2(cox-2) inhibitors
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
ZA9811178B (en) Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.
EP1443925B8 (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
HK1044545A1 (en) Human beta-secretase enzyme, inhibitors and their compositions and uses
WO2003086408A8 (en) Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
AU1025899A (en) Carboline derivatives as cgmp phosphodiesterase inhibitors
MY129445A (en) Compositions for treating inflammatory response
NO20010684L (en) Substituted 1,8-naphthyridin-4 (1H) -one as phosphodiesterase 4 inhibitors
AU2001238665A1 (en) Method of identifying partial agonists of the a2a receptor
ZA9711317B (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them.
AU2001261835A1 (en) Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists
WO2002028861A8 (en) Methods and compounds for treating proliferative diseases
ZA200204510B (en) Imidazopyridine derivatives used as phosphodiesterase VII inhibitors.
AU2002221753A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
NO20015062D0 (en) Substituted 3-cyano- [1.7], [1.5] and [1.8] -naphthyridine inhibitors for tyrosine kinases
AU4138601A (en) Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP